Efficacy of Radiotherapy In Oligometastatic Esophageal Squamous Cell Cancer Patients: New Evidence From A Retrospective Study

Abstract Background: The optimal chemotherapy regimen for refractory esophageal squamous cell cancer patients is uncertain. Our retrospective study assessed the efficacy and safety of irinotecan plus raltitrexed in esophageal squamous cell cancer patients who were previously treated with multiple systemic therapies. Methods: Between January 2016 and December 2018, records of 38 esophageal squamous cell cancer patients who underwent irinotecan plus raltitrexed chemotherapy after at least one line of chemotherapy were reviewed. Efficacy assessment was performed every two cycles according to the RECIST version 1.1. Results: A total of 95 cycles of chemotherapy were administered, and the median course was 3 (range 2–6). There was no treatment-related death. Nine patients had partial response, 21 had stable disease and 8 had progressive disease. The overall objective response rate was 23.68% (9/38) and the disease control rate was78.94% (30/38). After a median follow-up of 18.5 months, the median progression-free survival and overall survival were 105 days and 221 days respectively. There were 5 patients (13.15%) with grade 3/4 leukopenia, 3 patients (7.89%) with grade 3/4 neutropenia and 1 patient (2.63%) with grade 3/4 diarrhea. Conclusions: The combination of irinotecan plus raltitrexed was effective for pretreated esophageal squamous cell cancer patients. Further studies are needed to determine the optimal dose of the two drugs.

Download Full-text

Low cardiac dose and neutrophil-to-lymphocyte ratio predict overall survival in inoperable esophageal squamous cell cancer patients after chemoradiotherapy

Scientific Reports ◽

10.1038/s41598-021-86019-2 ◽

2021 ◽

Vol 11 (1) ◽

Author(s):

Yu-Chieh Ho ◽

Yuan-Chun Lai ◽

Hsuan-Yu Lin ◽

Ming-Hui Ko ◽

Sheng-Hung Wang ◽

...

Keyword(s):

Overall Survival ◽

Cancer Patients ◽

Squamous Cell ◽

Squamous Cell Cancer ◽

Performance Status ◽

Cell Cancer ◽

Esophageal Squamous Cell Cancer ◽

Lymphocyte Ratio ◽

Cardiac Dose

AbstractWe aimed to determine the prognostic significance of cardiac dose and hematological immunity parameters in esophageal cancer patients after concurrent chemoradiotherapy (CCRT). During 2010–2015, we identified 101 newly diagnosed esophageal squamous cell cancer patients who had completed definitive CCRT. Patients' clinical, dosimetric, and hematological data, including absolute neutrophil count, absolute lymphocyte count, and neutrophil-to-lymphocyte ratio (NLR), at baseline, during, and post-CCRT were analyzed. Cox proportional hazards were calculated to identify potential risk factors for overall survival (OS). Median OS was 13 months (95% confidence interval [CI]: 10.38–15.63). Univariate analysis revealed that male sex, poor performance status, advanced nodal stage, higher percentage of heart receiving 10 Gy (heart V10), and higher NLR (baseline and follow-up) were significantly associated with worse OS. In multivariate analysis, performance status (ECOG 0 & 1 vs. 2; hazard ratio [HR] 3.12, 95% CI 1.30–7.48), heart V10 (> 84% vs. ≤ 84%; HR 2.24, 95% CI 1.26–3.95), baseline NLR (> 3.56 vs. ≤ 3.56; HR 2.36, 95% CI 1.39–4.00), and follow-up NLR (> 7.4 vs. ≤ 7.4; HR 1.95, 95% CI 1.12–3.41) correlated with worse OS. Volume of low cardiac dose and NLR (baseline and follow-up) were associated with worse patient survival.

Download Full-text